Performance characteristics of an FT MS‐based workflow for label‐free differential MS analysis of human plasma: standards, reproducibility, targeted feature investigation, and application to a model of controlled myocardial infarction

Proteomics is undergoing a rapid transformation from a qualitative global peptide sequencing discipline into a quantitative, reproducibility‐driven practice. Nowhere is this more evident than in the rapidly expanding field of protein biomarker discovery where the general goal is to uncover statistically robust patterns of differential expression between or among subjects/samples representing distinct biological/temporal states. This report presents the analytical characterization of a label‐free LC FT‐ICR‐MS workflow for differential proteomics analysis of human plasma. The key elements discussed include (i) methodologies for performing properly replicated experiments with highly reproducible sample preparation and analysis, including the use of internal standards to quantify variance at different steps in the process, (ii) a new methodology for performing sample re‐analysis that uses off‐line targeted robotic acquisition of complementary spectral data (e.g. ECD and/or IRMPD) to enhance the identification of differentially expressed peptides/proteins, and (iii) data processing pipelines capable of integrating the automatic statistical analysis of the label‐free (LC‐) MS signal, together with the intuitive and highly interactive curation and annotation of differential features using the output from standard sequence database search programs. We illustrate the application of the complete sample‐to‐annotated‐differential‐peptides (‐proteins) workflow by describing the acquisition and analysis of a large multidimensional dataset from patients undergoing a controlled myocardial infarction resulting in an experimental setup in which each patients serve as their own control. Furthermore, we discuss a couple illustrative examples of mid‐level proteins observed in this study whose plasma concentrations change consistently within and across patients, in a treatment‐ and time‐dependent fashion.

[1]  Y K Wang,et al.  Inverse 18O labeling mass spectrometry for the rapid identification of marker/target proteins. , 2001, Analytical chemistry.

[2]  J. Williamson,et al.  Regulation of glutamate metabolism and interactions with the citric acid cycle in rat heart mitochondria. , 1973, The Journal of biological chemistry.

[3]  S. Carr,et al.  Reporting Protein Identification Data , 2006, Molecular & Cellular Proteomics.

[4]  Matthew Davison,et al.  Validation and development of fluorescence two‐dimensional differential gel electrophoresis proteomics technology , 2001, Proteomics.

[5]  Jennifer N. Sutton,et al.  Low‐molecular‐weight human serum proteome using ultrafiltration, isoelectric focusing, and mass spectrometry , 2004, Electrophoresis.

[6]  Jacob D. Jaffe,et al.  PEPPeR, a Platform for Experimental Proteomic Pattern Recognition*S , 2006, Molecular & Cellular Proteomics.

[7]  Frederick P Roth,et al.  Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.

[8]  M. Karas,et al.  Matrix-assisted ultraviolet laser desorption of non-volatile compounds , 1987 .

[9]  Sharon Chen,et al.  Mass spectrometry-based quantitative proteomic profiling. , 2005, Briefings in functional genomics & proteomics.

[10]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[11]  Koichi Tanaka,et al.  Protein and polymer analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry , 1988 .

[12]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[13]  M. Girolami,et al.  Clinical proteomics: A need to define the field and to begin to set adequate standards , 2007, Proteomics. Clinical applications.

[14]  P. Roepstorff,et al.  Quantitation of peptides and proteins by matrix-assisted laser desorption/ionization mass spectrometry using (18)O-labeled internal standards. , 2000, Rapid communications in mass spectrometry : RCM.

[15]  J. Enghild,et al.  Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. , 2003, The Biochemical journal.

[16]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[17]  Bin Liu,et al.  3‐Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS‐induced neurotoxicity , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  M. Mann,et al.  Electrospray Ionization for Mass Spectrometry of Large Biomolecules , 1990 .

[19]  M. Wiener,et al.  Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. , 2004, Analytical chemistry.

[20]  Sharon Chen.  Mass spectrometry-based quantitative proteomic , 2005 .

[21]  R. Mott,et al.  Pigment epithelium‐derived factor (PEDF) is an endogenous antiinflammatory factor , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  M. Mann,et al.  Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap*S , 2005, Molecular & Cellular Proteomics.

[23]  Richard D. Smith,et al.  Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications* , 2006, Molecular & Cellular Proteomics.

[24]  G. Hortin.  Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? , 2005, Clinical chemistry.

[25]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[26]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[27]  G. Chader.  PEDF: Raising both hopes and questions in controlling angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.